Breast Cancer

Sara M. Tolaney, MD, MPH, concludes the program with advice for community oncologists who are treating patients with breast cancer.

ERBB2, FAT3, and FRS2 alterations appear to correlate with improved progression-free survival with ribociclib compared with placebo in patients with advanced breast cancer.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for those with hormone receptor–positive breast cancer.

Results from an updated analysis of the DESTINY-Breast04 trial indicate an efficacy improvement when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.

The phase 3 KEYNOTE-756 trial yielded an increased pathological complete response for those with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer receiving pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy.

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.

Five-year data from the monarchE trial support adding adjuvant abemaciclib to endocrine therapy for patients with hormone receptor–positive, HER2-negative breast cancer.

A breast oncologist looks to the future of breast cancer treatment and discusses emerging therapies and ongoing clinical trials.

Expert perspectives on the treatment landscape for triple-negative breast cancer and the evolving role of immunotherapy in this space.

Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.

Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Accommodating supportive therapies such as fertility and hair follicle preservation may help increase trial recruitment among younger patients with breast cancer, according to Monique Gary, DO, MSc, FACS.

Sara M. Tolaney, MD, MPH, reviews key clinical trial data recently updated in the metastatic HER2+ breast cancer treatment space.

A medical oncologist offers clinical insights on the evolving treatment landscape for patients with HER2+ breast cancer.

While the majority of patients with breast cancer are women, men need to be considered when designing clinical trials.

Findings suggest that sensitive circulating tumor DNA analysis may be a valuable tool for guiding neoadjuvant treatment decision-making in early-stage triple-negative breast cancer.

Data from a study highlight that the breast cancer makes up the highest number of early-onset disease cases compared with other cancer types from 2010 to 2019, although overall cancer morality appears to have decreased.

Paolo Tarantino, MD, discusses how drug prices within the United States are affecting the treatment of breast cancer.

In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.

A comprehensive overview of the treatment landscape in early-stage breast cancer, with a focus on CDK4/6 and PARP inhibitors.

Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.

Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

Expert insights on biomarker testing in breast cancer, with a focus on key markers associated with specific subtypes.

Sara M. Tolaney, MD, MPH, an expert breast oncologist, reviews the overall treatment landscape for breast cancer.

The safety and tolerability of IDE161 is being assessed as part of a phase 1 trial in solid malignancies including breast cancer.

Monique Gary, DO, MSc, FACS, discusses emerging data on early-onset cancers, including breast cancer which had the highest incidence in this population.

A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.

The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.

Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.